Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2025
Product Development

Telix’s end-to-end radiopharma ambitions

With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Sep 17, 2024
Deals

Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program

Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Apr 24, 2024
Product Development

Next-wave radiopharmaceuticals: insights from AACR

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Sep 27, 2023
Emerging Company Profile

Biotheus: fully-integrated mAb platform for optimized fast-follower products

China-based Biotheus goes from discovery to IND submission in about two years
BioCentury | Jun 30, 2023
Emerging Company Profile

Ratio: tuning the pharmacokinetics of radiotherapies

The company’s Trillium platform combines the tumor penetration of small molecules with the staying power of mAbs for its actinium-225 therapies
BioCentury | Mar 6, 2023
Finance

As clinical evidence mounts for bispecific, VCs back Bicara with $108M series B

Red Tree branches beyond West Coast sweet spot to co-lead with RA Capital in backing Biocon spinout
BioCentury | Nov 12, 2022
Product Development

Modalities merge into new platforms at SITC 2022

Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

BioCentury | Nov 10, 2017
Financial News

Telix raises A$50M in Australian IPO

Items per page:
1 - 10 of 58